JP2003501022A5 - - Google Patents

Download PDF

Info

Publication number
JP2003501022A5
JP2003501022A5 JP2001500744A JP2001500744A JP2003501022A5 JP 2003501022 A5 JP2003501022 A5 JP 2003501022A5 JP 2001500744 A JP2001500744 A JP 2001500744A JP 2001500744 A JP2001500744 A JP 2001500744A JP 2003501022 A5 JP2003501022 A5 JP 2003501022A5
Authority
JP
Japan
Prior art keywords
isolated polypeptide
amino acid
seq
group
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001500744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003501022A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/011862 external-priority patent/WO2000073431A2/en
Publication of JP2003501022A publication Critical patent/JP2003501022A/ja
Publication of JP2003501022A5 publication Critical patent/JP2003501022A5/ja
Withdrawn legal-status Critical Current

Links

JP2001500744A 1999-05-27 2000-05-25 イオンチャネルコンダクタンスを測定するための方法およびその組成物 Withdrawn JP2003501022A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13617499P 1999-05-27 1999-05-27
US60/136,174 1999-05-27
PCT/US2000/011862 WO2000073431A2 (en) 1999-05-27 2000-05-25 Methods and compositions for measuring ion channel conductance

Publications (2)

Publication Number Publication Date
JP2003501022A JP2003501022A (ja) 2003-01-14
JP2003501022A5 true JP2003501022A5 (enExample) 2007-07-12

Family

ID=22471672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001500744A Withdrawn JP2003501022A (ja) 1999-05-27 2000-05-25 イオンチャネルコンダクタンスを測定するための方法およびその組成物

Country Status (5)

Country Link
US (1) US20070238168A1 (enExample)
EP (1) EP1180142A2 (enExample)
JP (1) JP2003501022A (enExample)
AU (1) AU4980200A (enExample)
WO (1) WO2000073431A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
CA2393538A1 (en) * 1999-12-14 2001-06-21 Pharmacia & Upjohn Company Human ion channels
GB0003069D0 (en) * 2000-02-11 2000-03-29 Cambridge Drug Discovery Ltd Improved assay
DE10006309A1 (de) * 2000-02-12 2001-08-23 Aventis Pharma Gmbh Verfahren zur Identifizierung von Substanzen, die die Aktivität von hyperpolarisationsaktivierten Kationen-kanälen modulieren
WO2002016357A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282875A1 (en) 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002061074A1 (fr) * 2001-01-30 2002-08-08 Takeda Chemical Industries, Ltd. Nouvelle proteine et adn la comprenant
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036041A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
CA2458375A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza¬2.2.1|bicycloheptanes for the treatment of disease
CA2462453C (en) 2001-10-02 2009-07-28 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
CA2466375A1 (en) 2001-11-08 2003-05-15 Pharmacia & Upjohn Company Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
MXPA04004373A (es) 2001-11-09 2004-08-11 Upjohn Co Compuestos heterociclicos condensados con fenilo azabiciclo para el tratamiento de enfermedades.
EP1480977A2 (en) 2002-02-15 2004-12-01 PHARMACIA & UPJOHN COMPANY Substituted aryl compounds for treatment of disease
CA2476624A1 (en) 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
CA2476681A1 (en) 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
WO2003072578A1 (en) * 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
US7358057B2 (en) 2002-05-09 2008-04-15 Memory Pharmaceuticals Corporation QM-7 and QT-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells
US7176198B2 (en) 2002-08-01 2007-02-13 Pfizer Inc. 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
EP1581558A2 (en) * 2003-01-07 2005-10-05 Neuromed Technologies, Inc. Fluorescence based t-type channel assay
US7488599B2 (en) * 2004-10-15 2009-02-10 Monell Chemical Senses Center Methods for culturing mammalian taste cells
US7732607B2 (en) 2005-08-22 2010-06-08 Anatoly Mazurov Heteroaryl-substituted diazatricycloalkanes and methods of use thereof
JP5241255B2 (ja) * 2008-02-01 2013-07-17 生化学工業株式会社 関節痛の評価方法
US20110098312A1 (en) 2008-05-12 2011-04-28 Targacept ,Inc Methods for preventing the development of retinopathy by the oral administration of nnr ligands
EP2344636B1 (en) * 2008-10-09 2017-12-06 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
CA2797356C (en) 2010-04-26 2020-12-29 Novartis Ag Improved cell culture medium
US10538571B2 (en) 2017-11-27 2020-01-21 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases
CN111378025A (zh) * 2020-03-26 2020-07-07 集美大学 河豚毒素结合蛋白tfPSTBP2、核苷酸序列、其多克隆抗体及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670113A (en) * 1991-12-20 1997-09-23 Sibia Neurosciences, Inc. Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same
DE69434067T2 (de) 1993-03-08 2006-03-02 Merck & Co., Inc. Menschliche neuronale nikotin-acetylcholin-rezeptor-verbindungen und methoden ihres einsatzes
US6323000B2 (en) * 1996-12-20 2001-11-27 Clark A. Briggs Variant human α7 acetylcholine receptor subunit, and methods of production and uses thereof
AU9673198A (en) * 1997-10-02 1999-04-27 Aclara Biosciences, Inc. Capillary assays involving separation of free and bound species

Similar Documents

Publication Publication Date Title
JP2003501022A5 (enExample)
JP2005505579A5 (enExample)
JP2001520044A5 (enExample)
JP2001520045A5 (enExample)
AU4778101A (en) Novel polypeptides, and nucleic acids encoding the same
NZ504548A (en) Polypeptides and nucleic acids encoding human chordin
DK1133565T3 (da) Generering af specifikke bindingspartnere til (poly)peptider, som der kodes for af genomiske DNA-fragmenter eller EST'er
DE69838143D1 (de) Antimikrobielle peptide
JP2003533186A5 (enExample)
WO2002016418A3 (en) An iap binding peptide or polypeptide and methods of using the same
JP2005516996A5 (enExample)
JP2005502332A5 (enExample)
DK1383874T3 (da) Varianter af lipogygenase og deres anvendelse
WO2002008426A3 (en) Fh-binding protein of streptococcus pneumoniae
EP1501936A4 (en) PROTEIN FAMILY OF CYTOKINE
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
RU2007119376A (ru) Тимус - специфический белок
EP1688498A4 (en) RECOMBINANT PROTEIN WITH CANCER SUPPRESSIVE EFFECT, ITS CODING GENE AND ITS USE
AU5776799A (en) Modified hcv peptide vaccines
JP2003334088A5 (enExample)
WO2004064780A3 (en) Peptide-based angiogenesis inhibitors and methods of use thereof
JP2024118709A5 (enExample)
JP2006515984A5 (enExample)
JP2005535281A5 (enExample)
SG170092A1 (en) Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof